Combined Inhibition of MDM2 and BCR-Abl Tyrosine Kinase Targets Chronic Myeloid Leukemia Stem/Progenitor Cells in a Murine Model

Haematologica- Italy

doi 10.3324/haematol.2019.219261

Full Text

Abstract

Available in

Categories

Date

August 1, 2019

Authors

Elisha J. Dettman

Michael Cardone

Michael Andreeff

Publisher

Ferrata Storti Foundation (Haematologica)

Related search

Adoptive Immunotherapy of BCR-ABL-induced Chronic Myeloid Leukemia-Like Myeloproliferative Disease in a Murine Model

English

Incidence and Outcome of BCR‐ABL Mutated Chronic Myeloid Leukemia Patients Who Failed to Tyrosine Kinase Inhibitors

Cancer Medicine

Cancer Research

Nuclear Medicine

English

Differential Genomics and Transcriptomics Between Tyrosine Kinase Inhibitor-Sensitive and -Resistant BCR-ABL-dependent Chronic Myeloid Leukemia

English

BCR-ABL Tyrosine Kinase

Science-Business eXchange

English

Tyrosine Kinase Inhibitors in BCR-ABL Positive Acute Lymphoblastic Leukemia

English

Chronic Myeloid Leukemia Stem Cells Possess Multiple Unique Features of Resistance to BCR-ABL Targeted Therapies

Cancer Research

English

Inhibitory Effects of Omacetaxine on Leukemic Stem Cells and BCR-ABL-induced Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Mice

Cancer Research

English

Tyrosine Kinase Inhibition in Acute Myeloid Leukemia

Leukemia and Lymphoma

Cancer Research

English

Current Status of ABL Tyrosine Kinase Inhibitors Stop Studies for Chronic Myeloid Leukemia

Stem Cell Investigation

English